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ABSTRACT 27 
Adeno-associated virus type-2 is known to inhibit replication of herpes simplex virus type-1 28 
(HSV-1). This activity has been linked to the helicase- and DNA-binding domains of the 29 
Rep68/78 proteins. Here, we show that Rep68 can bind to consensus Rep-binding sites on 30 
the HSV-1 genome and that the Rep-helicase activity can inhibit replication of any DNA if 31 
binding is facilitated. Therefore we hypothesize that inhibition of HSV-1 replication involves 32 
direct binding of Rep68/78 to the HSV-1 genome. 33 
Keywords:  AAV2; HSV-1; Rep-binding site; Rep helicase.  34 
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FINDINGS 35 
Adeno-associated virus type-2 (AAV2) is a nonpathogenic human parvovirus with a unique 36 
biphasic life cycle. In the absence of a helper virus, AAV2 establishes a latent infection while 37 
in the presence of a helper virus, such as adenovirus type-2 (AdV2), herpes simplex virus 38 
type-1 (HSV-1) or human papillomavirus type-16 (HPV-16), it undergoes lytic replication (1–39 
4). The AAV2 genome is a single-stranded (ss) DNA of 4,680 nucleotides, which is packaged 40 
into an icosahedral capsid with a diameter of approximately 20 nm (5). The genome harbors 41 
two clusters of genes, rep and cap, which are flanked by inverted terminal repeats (ITRs). 42 
The ITRs form hairpin structures and contain a Rep-binding site (RBS) and a terminal 43 
resolution site (trs), which together act as viral origin of DNA replication (6, 7). The cap gene 44 
is transcribed from the p40 promoter and encodes the capsid proteins VP1, VP2, and VP3, 45 
which differ in their N-termini due to alternative start codons (8, 9). In addition, a nested 46 
open-reading frame (ORF) within the cap gene encodes a protein designated assembly-47 
activating protein (AAP), which is believed to be required for AAV2 capsid assembly in the 48 
nucleolus (10, 11). The rep gene encodes the Rep proteins, which are synthesized in four 49 
different forms due to transcription from two different promoters, p5 and p19, and alternative 50 
splicing of an intron near the C-terminal end (12). The different Rep proteins are termed 51 
Rep40, Rep52, Rep68, and Rep78 according to their apparent molecular weight. The Rep 52 
proteins are involved in diverse processes during the viral life cycle, such as DNA replication, 53 
regulation of gene expression, genome packaging, and site-specific genomic integration (13–54 
18). 55 
HSV-1 belongs to the subfamily of the Alphaherpesvirinae and is the reagent causing 56 
mucosal eruptions at the site of infections, which can reoccur at the same site upon 57 
reactivation from latency (19, 20). The HSV-1 virion is built up by three structural 58 
components which are the capsid, the tegument and the surrounding envelope. The viral 59 
genome is a linear double stranded DNA molecule of 152 kb in size and has a unique 60 
structure. It is divided into two covalently joined segments, which contains unique segments 61 
(UL, US) and inverted repeat regions (TRL, IRL, IRS, and TRS). The IR sequences link the L 62 
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and S segments (Fig. 1A). HSV-1 gene expression and replication occurs in a temporally 63 
regulated cascade; immediate early (IE), early (E) and late (L). IE proteins mainly exhibit 64 
regulatory functions and initiate expression of the E genes. The E proteins comprise 65 
enzymes necessary for viral DNA replication and are therefore required for the expression of 66 
some of the L genes, as expression of these genes relies on DNA replication. All viral 67 
replication events take place in the nucleus within distinct areas termed replication 68 
compartments (RCs) (21). In the course of viral DNA replication, these RCs grow 69 
continuously and four different stages (I-IV) can be distinguished according to RCs staining 70 
patterns (22–24). The minimal set of HSV-1 proteins required for initiating AAV2 replication 71 
consists of the E proteins UL5, UL8, and UL52, which together form the HSV-1 72 
helicase/primase complex, as well as the ssDNA binding protein ICP8 (UL29) (25–27). In 73 
addition, the HSV-1 IE proteins ICP4 and ICP0, the E protein complex forming the HSV-1 74 
polymerase (UL30 and UL42) and the US1 gene product, strongly enhance AAV2 replication 75 
(26). AAV2 has developed strategies to inhibit helper virus replication, likely to reduce 76 
competition (24, 28–33). For example, expression of the AAV2 non-structural proteins 77 
Rep68/78 alone leads to a significant inhibition of HSV-1 DNA replication (24, 28). 78 
Specifically, we demonstrated that the AAV2 Rep protein domains responsible for the 79 
inhibition of HSV-1 DNA replication include the DNA-binding and the ATPase/helicase 80 
activities, while the endonuclease activity is not required (28). We also showed that Rep-81 
mediated inhibition of HSV-1 occurs even in absence of AAV DNA and is not due to 82 
alterations of HSV-1 immediate-early (IE) and early (E) gene expression, nor due to the Rep-83 
mediated induction of toxic stress in the cell, but rather occurs at the stage of HSV-1 DNA 84 
replication itself (28). We hypothesized that a possible mechanism of Rep68/78-mediated 85 
inhibition of HSV-1 DNA replication may involve binding of Rep proteins to consensus Rep-86 
binding sites (RBS) on the HSV-1 genome and modification of the bound DNA substrate via 87 
the Rep helicase activity. To investigate this possibility, we now addressed the following two 88 
questions: (i) do consensus RBS exist on the HSV-1 genome and if so, can AAV2 Rep 89 
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proteins bind to these sites and (ii) can the AAV2 Rep helicase activity inhibit replication of 90 
any DNA substrate when binding is facilitated? 91 
We addressed the first question by screening the wild type (wt) HSV-1 (strain F) genome for 92 
the minimal consensus RBS motif GAGYGAGC as a prerequisite for the ability of Rep to 93 
specifically bind to dsDNA templates via its DNA-binding domain (34). We found that such 94 
sites are indeed present as shown in Fig. 1. All consensus RBS are located within coding 95 
sequences of genes found in the unique long (UL) segment of the HSV-1 genome (Fig. 1A). 96 
Sequence alignment revealed that all putative HSV-1 RBS (pRBS) consist of two complete 97 
GAGC repeats with the exception of pRBS No. 7, which contains a T in place of a C at 98 
position 74604 (nt) but still complies with the GAGYGAGC consensus sequence (Fig. 1B). 99 
Importantly, no consensus trs (CCAACT) (6, 18) was found within 8-13 nt after any putative 100 
HSV-1 RBS, excluding the existence of a AAV2 integration site at these positions on the 101 
HSV-1 genome (35). We next tested the capability of AAV2 Rep proteins to bind via the 102 
DNA-binding domain to putative HSV-1 RBS by electrophoretic mobility-shift assays (EMSA) 103 
using purified His-tagged Rep68 proteins (His-Rep68). We designed 37-mer duplexed 104 
oligonucleotides harboring selected putative RBSs (No. 1-5; Fig. 1B, light grey box), which 105 
were radioactively labelled with [γ-32P]-ATP. An oligonucleotide containing the native RBS 106 
from the AAV2 inverted terminal repeat (ITR) was used as the positive control. An 107 
oligonucleotide containing a random sequence from within the UL44 gene harboring no 108 
putative RBS was used as negative control. Approximately 5 fmol of each duplexed 109 
oligonucleotide was incubated with 0, 120, or 240 ng of His-Rep68 protein for 30’ at room 110 
temperature (RT) and then subjected to 4% polyacrylamide gel electrophoresis. After 3h, the 111 
gel was dried and exposed to Fujifilm Imaging Plates, which were developed with a Fujifilm 112 
FLA-7000 Image Plate reader. For all oligonucleotides No. 1-5 examined we observed a 113 
dose-dependent shift compared to the unbound DNA template (Fig. 2A). The %-shift values 114 
for the oligonucleotides No. 1-5 were slightly lower (63-76%) than that of the positive control 115 
(ITR) (87%). The negative control oligonucleotide (nc) was shifted 5% only. Multiple shifted 116 
bands of the oligonucleotides No. 1-5 as well as the ITR-oligonucleotide were observed, 117 
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possibly due to the different oligomerization states Rep68 can form on ds DNA templates 118 
(36–38). To confirm that binding of His-Rep68 to the pRBS is indeed specific, we performed 119 
EMSAs as described above, except that 5 fmol of non-labeled (cold) duplex ITR 120 
oligonucleotide was used as competitor. The cold ITR competitor DNA appeared to prevent 121 
binding of His-Rep68 to the pRBS oligonucleotides, as no shift was observed under these 122 
conditions for the oligonucleotides No. 1-3 and a clearly reduced shift for the oligonucleotides 123 
No. 4-5 (Fig. 2B). 124 
In order to investigate whether AAV2 Rep68 is able to bind to consensus RBS on the HSV-1 125 
genome also in HSV-1 infected cells, we performed chromatin-immunoprecipitation (ChIP) 126 
assays followed by quantitative (q)PCR analysis (ChIP-qPCR). For this, Vero cells were 127 
transfected with plasmids expressing either Rep68, or Rep52 proteins fused with enhanced 128 
green fluorescent protein (EGFP). The next day, the cells were infected with wt HSV-1 (strain 129 
F) at an MOI of 40. At 16 h after infection, the cells were fixed with 4% paraformaldehyde 130 
(PFA), sonicated for 10min and processed for ChIP using the GFP-Trap® kit (Chromotek). 131 
The immunoprecipitated DNA oligonucleotides were then analyzed by qPCR using primers 132 
specific for the consensus RBS No. 1-9 (Fig. 1 and Table. 1). Primers for amplification of a 133 
sequence from the HSV-1 genome containing no proximal RBS (US1) served as a negative 134 
control (Table. 1). The qPCR mix was the following: 0.25µl of each primer [10µM], 10µl of 135 
SYBR® Green mix (SYBR® Green PCR Master Mix, Applied Biosystems) and 2.5µl of DNA in 136 
a final volume of 20µl. The reaction was carried out as follows: 95°C for 3min, 39x (95°C for 137 
15sec, 60°C for 1min) followed by a final elongation step at 95°C for 10min. The raw Ct 138 
values were analyzed using the percent input (%-INPUT) method (%-INPUT = 100*2 ΔCt, 139 
whereas ΔCt = (Ct [Input] - Log2 (Input Dilution Factor) - Ct [ChIP]). For each primer pair 140 
tested (no RBS and putative RBS 1-9), the %-INPUT values were calculated from cells 141 
expressing either Rep52-GFP (light grey bars) or Rep68-GFP (dark grey bars) (Fig. 2C). 142 
Using this data we next addressed (i) whether Rep68 binding to the HSV-1 DNA is more 143 
efficient at a pRBS and (ii) whether the DNA-binding domain of Rep68 is required for binding. 144 
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To address the first point, we calculated the difference between each value obtained from 145 
binding of Rep68-GFP to a pRBS and the control value (no RBS) which was set as 1. The 146 
graph in Fig. 2D shows that Rep68-GFP can bind more efficiently to the HSV-1 DNA that 147 
harbours a pRBS than to the control with no pRBS, with one exception; binding to pRBS No. 148 
7 was not more efficient than binding to the control with no pRBS, likely because the pRBS 149 
No. 7 consensus sequence is slightly aberrant (Fig. 1B). Nevertheless, we can conclude that 150 
binding of Rep68 to HSV-1 DNA is more efficient when it harbors a pRBS. To address the 151 
second point, we calculated the difference (%-INPUT ratio) between the Rep68-GFP and the 152 
Rep52-GFP values for each consensus binding site No. 1-9 and the negative control (no 153 
RBS). The ratios were normalized to the no RBS (US1) control ratio and are shown in Fig. 154 
2D. As expected, the ratio between Rep68-GFP and Rep52-GFP was the smallest in the 155 
absence of a consensus RBS (no RBS) and was set as 1. The ratios for all pRBS No. 1-9 156 
were clearly higher and were statistically significant for pRBS No. 3-8. We can therefore 157 
conclude that the DNA-binding domain of Rep68 enhances binding to pRBS in this assay. To 158 
appreciate the quality of the binding of Rep68 to pRBS, we tested binding of a HSV-1 DNA 159 
binding protein, ICP4, to the ICP4-binding site in the HSV-1 ICP0 promoter relative to an 160 
unspecific DNA that does not contain an ICP4 binding site (US1). For this, we infected Vero 161 
cells with a recombinant HSV-1 (rHSVEYFP-ICP4) which expresses the ICP4 protein fused 162 
to the enhanced yellow fluorescent protein (EYFP) (39). One day later, we processed the 163 
cells for ChIP and qPCR as described above. We found that the ICP4 protein binds 164 
specifically to the ICP0 promoter. Binding efficiency was approximately 2.5-fold higher to the 165 
ICP0 promoter sequence than to the US1 control sequence (Fig. 2F) and is comparable to 166 
previous findings (40). We can therefore conclude that binding of AAV2 Rep68 to the HSV-1 167 
DNA at a pRBS is at least as efficient as binding of the native HSV-1 DNA-binding protein 168 
ICP4 to its binding site in the HSV-1 ICP0 promoter (Fig. 2F). 169 
To investigate the question whether the AAV2 Rep helicase domain can inhibit replication of 170 
any DNA substrate when binding is facilitated, we used a well-established assay to 171 
investigate the replication of HSV-1 and AAV2 DNA (21, 24, 41, 42). Briefly, cells are co-172 
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transfected with two plasmids; the first contains 40 binding sites for the lac repressor protein 173 
LacI and an HSV-1 origin of DNA replication (pHSV-lacO), and the second plasmid encodes 174 
the lac-operon binding motif of LacI fused with enhanced yellow fluorescent protein (EYFP-175 
LacI). In presence of HSV-1 helper functions, pHSV-lacO replicons (and therefore the 176 
binding sites for LacI) are amplified (because of the HSV-1 origin of DNA replication) and 177 
recruitment of autofluorescent LacI protein then allows visualization of pHSV-lacO DNA 178 
replication. We have now modified this assay by transfecting a third plasmid encoding the 179 
AAV2 Rep40/52 proteins, which contain the helicase but not the DNA binding domain, fused 180 
with the lac-operon binding motif of LacI (Rep40/52-LacI) (Fig. 3, A and B). The modified 181 
Rep40/52 proteins are prone to bind to lac-operon binding sequences present on the pHSV-182 
lacO replicon and therefore allowed us to study the effect of the Rep helicase activity 183 
independent of the interaction between the AAV2 Rep DNA-binding domain and the RBS. 184 
The results shown in Fig. 3 (C-E) demonstrate that the Rep40/52-LacI proteins were indeed 185 
able to inhibit the replication of pHSV-lacO, as cells containing mature stage IV replication 186 
compartments (RCs) were not observed (Fig. 3C, panel n). By contrast, the Rep40/52 187 
proteins, which lack any DNA binding domain, did not prevent the formation of mature stage 188 
IV HSV-1 RCs (Fig. 3C, panel i). Neither did Rep40/52K340H-LacI proteins, which can bind 189 
to the pHSV-lacO replicon but contain a point mutation that inactivates the helicase activity 190 
(43), although the numbers of stage IV RCs was reduced by approximately 50%, indicating 191 
that these fusion proteins can inhibit the replication of the HSV-1 replicon to some extent 192 
(Fig. 3C panel s). Also, in the cultures transfected with the Rep40/52-LacI encoding plasmid 193 
the frequency of stage III RCs was reduced by approximately 3-fold (Fig. 3C, panel m) while 194 
the frequency of cells showing diffuse EYFP-fluorescence (stage I; no RCs) was much higher 195 
when compared with the control cultures: no Rep (Fig. 3C, panel a), Rep40/52 (Fig. 3C, 196 
panel f) and Rep40/52K340H-LacI (Fig. 3C, panel p). We confirmed that Rep40/52-LacI 197 
proteins indeed bind to LacI-repressor binding sites on the pHSV-lacO reporter DNA by 198 
determining the degree of colocalization of the LacI-EYFP and the Rep AF594 signals in the 199 
merged images of panels l-n and q-s (Fig. 3E). The colocalization values in the smaller RCs 200 
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(stage II and III) were lower in trend then the values of the mature RCs (stage IV). This 201 
observation may be explained as follows: at early time points when the numbers of pHSV-202 
lacO replicons are small, there is more competition for Lac-repressor binding sites between 203 
the Rep-LacI construct and the LacI-EYFP reporter protein. The distribution of stage I-IV RCs 204 
was comparable in cells transfected with the Rep40/52 (Fig. 3C, panels f-i) and the 205 
Rep40/52K340H-LacI (Fig. 3C, panels p-s) encoding plasmids, indicating that Rep40/52-LacI 206 
competition with EYFP-LacI did not interfere with detection of RCs. Moreover, while 207 
Rep68/78 can efficiently inhibit wtHSV-1 DNA replication (24, 28), Rep40/52, Rep40/52-LacI, 208 
and Rep40/52K340H-LacI do not (reference 28 and data not shown). These results indicate 209 
that the AAV2 Rep helicase activity in absence of the Rep DNA binding and endonuclease 210 
activities can inhibit the replication of any DNA template as long as it can bind to it. Of note, 211 
we have observed 5.3±9.2% and 17.3±4.6% of cells showing numerous nuclear foci when 212 
transfected with Rep40/52-LacI (Fig. 3C, panel o) or the helicase mutant Rep40/52K340H-213 
LacI (Fig. 3C, panel t) respectively. Such foci were not observed when cells were transfected 214 
with the Rep40/52 (Fig. 3C, panel j) encoding plasmid or the empty backbone plasmid 215 
pcDNA3.1+ (Fig. 3C, panel e). Some of the foci represent background binding of EYFP-LacI 216 
to Lac-repressor binding sites on the pHSV-lacO input plasmid because foci were observed 217 
also in presence of pHSV-lacO and EYFP-LacI and absence of helpervirus (not shown). This 218 
hypothesis is supported also by the fact that Rep52-LacI proteins, which can also bind to the 219 
Lac-repressor binding sites on the pHSV-lacO replicons, co-localized with the numerous 220 
EYFP-LacI foci (Fig. 3C, insets panel o and t). While we do not know why the number of foci 221 
increases markedly in presence of Rep40/52-LacI constructs or absence of HSV-1 222 
helpervirus, similar patterns have been observed before to occur when HSV-1 replication is 223 
inhibited by treating the cells with viral polymerase inhibitors such as phosphonoacetic acid 224 
(PAA), transfection of Rep68/78 encoding plasmids, or by use of polymerase-deficient HSV-1 225 
(24, 44, 45). 226 
In this report we demonstrate that the AAV2 Rep68 protein is capable of binding to pRBS on 227 
the ds HSV-1 genome in silico, in vitro, and in HSV-1 infected cells. EMSA and ChIP-qPCR 228 
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data revealed that binding of Rep68 to consensus RBS is specific and requires the Rep 229 
DNA-binding domain. Moreover, Rep68 is not able to bind efficiently to random HSV-1 230 
sequences (UL44 and US1). In addition, we showed that the Rep helicase activity can inhibit 231 
replication of a random DNA substrate if binding is facilitated. 232 
Generally, replicative stress is rapidly sensitized in the cell by numerous stress response 233 
factors and pathways such as DNA-damage response (DDR) or DNA-damage tolerance 234 
(DDT) (Reviewed in 46). One of the best understood stress responses resembles the DDR 235 
pathway initiated by the sensor-kinase ataxia-telangiectasia mutated (ATM)- and Rad3-236 
related (ATR), which is activated upon stalling of the replication fork (RF). At a stalled RF, the 237 
helicase activity of the mini-chromosome maintenance protein complex (e.g. MCM2) is 238 
uncoupled from the replication complex and continues unwinding, which is generating a 239 
stretch of ssDNA recognized and covered by the replication protein A (RPA) (47–50). This 240 
leads to the activation of ATR, which then induces a DDR resulting in cell-cycle arrest 241 
allowing the cell to resolve the stalled RF (51–55). However, persisting replication stress can 242 
result in the collapse of the RF, associated with double-strand breaks (DSBs) and the 243 
consecutive inhibition of DNA replication (56). 244 
Hence, we hypothesize that binding of Rep to consensus RBS and the helicase activity may 245 
generate a situation resembling a stalled RF, in particular when the Rep helicase activity is 246 
uncoupled from the replication activity, either because of the absence of a functional trs or 247 
the absence of the endonuclease activity. Support for this theory comes from previous 248 
observations which showed that the AAV2 Rep68/78 proteins induce a cellular DDR which is 249 
characterized by the activation of RPA and ATM, leading to an S-phase arrest (28, 57–59). It 250 
was initially hypothesized that the activation of ATM is a response to nicks induced by the 251 
endonuclease activity of Rep at multiple trs located on the cellular chromatin (59). However, 252 
we have shown in a later study that the activation of RPA and ATM also occurs with a 253 
Rep68/78 mutant lacking endonuclease activity (Y156F) and that the DNA-binding and 254 
ATPase/helicase activities of Rep are necessary for activation of these DNA damage 255 
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markers (28). We therefore hypothesize that the activation of RPA and ATM might in fact be 256 
due to Rep-induced dsDNA breaks caused by persistent stalling of RFs, although this 257 
possibility remains to be investigated. 258 
It has been shown that the AAV2 Rep proteins are also capable of binding to the DNA of 259 
other helperviruses, such as AdV. In particular, Rep68 proteins can bind specifically to the 260 
AdV E2A promoter (60) as well as to a 55-bp DNA fragment within the AdV major late 261 
transcription promoter (MLP) via interaction with the cellular TATA box-binding protein (TBP) 262 
(61). These interactions of Rep68 with the AdV genome are mediating inhibition of 263 
transcription and therefore may directly affect AdV replication. However, in contrast to HSV-264 
1, binding of Rep68 to the AdV genome occurs independently of consensus RBSs, and 265 
inhibition of AdV replication does not imply the Rep helicase activity. Whether the AAV2 Rep 266 
proteins are capable of binding to the HSV-1 genome independently of a consensus RBSs, 267 
e.g. via viral or cellular proteins that bind to the HSV-1 DNA, is a matter of current 268 
investigations. Of note, the Rep40/52 proteins, which have no DNA-binding domain, are not 269 
capable of binding to double-stranded (ds) DNA templates, neither to consensus RBS nor to 270 
random sequences. However, Rep40/52 can very well bind to single-stranded (ss) DNA 271 
templates, which is facilitated by two lysine residues (Lys-404 and Lys-406) located within 272 
the helicase domain (62). We indeed observed some unspecific binding of Rep52 to 273 
consensus RBS within the HSV-1 genome (Fig. 2C), which may occur when stretches of 274 
ssDNA are exposed naturally during replication of the HSV-1 genome. However, since 275 
Rep40/52 alone is not capable of inhibiting HSV-1 DNA replication (28), we consider that 276 
unspecific binding of Rep40/52 to consensus RBS on the HSV-1 genome may not exhibit 277 
sufficient binding capacity to inhibit HSV-1 DNA replication. 278 
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FIGURE LEGENDS 282 
Figure 1. The HSV-1 genome contains nine putative Rep-binding sites (pRBS). (A) The 283 
minimal AAV2 Rep-binding site motif GAGYGAGC was used to identify consensus Rep-284 
binding sites within the HSV-1 (strain F) genome, that can be divided into unique long (UL) 285 
and unique short (US) segments which are both flanked by internal and terminal inverted 286 
repeats (TRL, IRL, IRS, TRS). The arrowheads facing down represent pRBS located on the 287 
plus-strand and the arrowheads facing up represent pRBS located on the minus-strand. The 288 
pRBS were numbered randomly from 1 to 9 as indicated. The HSV-1 genes containing a 289 
consensus pRBS are highlighted. (B) Alignment of sequences from the AAV2 ITR and the 290 
nine HSV-1 pRBS identified in panel A. The consensus RBS (motif GAGYGAGC) and the trs 291 
located on the AAV2 ITR are indicated (dark grey boxes). Sequences analyzed in the in vitro 292 
experiments No. 1-5 are squared in a light grey box. The illustration was generated using the 293 
prettyplot function of the online tool EMBOSS (http://pro.genomics.purdue.edu/emboss/). The 294 
numbers on the right indicate the nucleotide (nt) position within the AAV2 genome (ITR) or 295 
the HSV-1 genome No. 1-9. Conserved nucleotides are indicated below as a schematic 296 
representation created with weblogo (63). 297 
Figure 2. Rep-binding assays. (A) Electrophoretic mobility shift assays (EMSA) were 298 
performed with purified His-tagged Rep68 proteins (His-Rep68) and radiolabeled duplex 299 
oligonucleotides No. 1-5 containing pRBS, the negative control (nc) or the positive control 300 
(ITR); see light grey box in Fig. 1B for oligonucleotide sequences. The amount (ng) of His-301 
Rep68 protein used is indicated at the top of the blot. (B) EMSA competition assays were 302 
performed with cold competitor DNA consisting of the positive control oligonucleotide (ITR), 303 
presented at equal-fold molar excess. The %-shift values were calculated for all the reactions 304 
and are shown below the blots. (C) Chromatin immuno-precipitation (ChIP) assays followed 305 
by qPCR (ChIP-qPCR) were performed with Vero cells (approx. 1.5x106 cells in a 6 cm cell 306 
culture dish) transfected with 0.5µg of a plasmid encoding either the Rep68-EGFP fusion 307 
protein (Rep68-GFP) or the Rep52-EGFP fusion protein (Rep52-GFP) and superinfected 308 
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with wtHSV-1 (strain F) at an MOI of 40. At 16 h after infection the cells were processed for 309 
ChIP as described in the text. The precipitated DNA was analyzed by qPCR using specific 310 
primers flanking the pRBS No. 1-9 on the HSV-1 genome or primers flanking a sequence of 311 
the HSV-1 US1 gene that contains no proximal pRBS (no RBS); Table.1. The data was 312 
quantified using the percentage input (%-INPUT) method as described in the text. (D) The 313 
Rep68-GFP values from panel C were normalized to the no RBS-control, which was set as 1. 314 
(E) The ratio between the Rep68-GFP and the Rep52-GFP values was calculated and 315 
normalized to the ratio of the control values (no RBS). Bars represent mean values and 316 
standard errors (SE) from 3-6 individual experiments. (F) Vero cells were infected with 317 
rHSVEYFP-ICP4 at an MOI of 5. Two days later, the cells were processed for ChIP-qPCR as 318 
described in the text. The qPCR was performed with primers flanking the ICP0 promoter 319 
(ICP0 prom.) or the US1 locus as a negative control. The resulting Ct values were analyzed 320 
using the percent input (%-INPUT) method. The results are shown as %-INPUT values (left) 321 
and the normalized %-INPUT values (right). Asterisks indicate statistically significant 322 
differences between the negative controls (no RBS/US1) and the corresponding binding sites 323 
on a paired two-tail students t-test (* = p<0.05; ** = p<0.01; *** = p<0.001). 324 
Figure 3. Inhibition of DNA replication by the AAV2 Rep helicase activity. (A) Schematic 325 
representation of the Rep constructs analyzed in this experiment. The functional protein 326 
domains of interest for this study are indicated. The arrow facing down indicates the splicing 327 
site of the Rep gene. (B) Western analysis of Rep40/52, Rep40/52-LacI, and 328 
Rep40/52K340H-LacI. Vero cells (200’000 cells/well) were transfected with 0.1µg of a 329 
plasmid encoding either Rep40/52, Rep40/52-LacI, Rep40/52K340H-LacI, or the empty 330 
plasmid backbone pcDNA3.1+ (no Rep). After 24h the cells were harvested and processed 331 
for Western blotting using a Rep-specific antibody (mouse-anti Rep-mAb, clone 303.9, 332 
Fitzgerald; 1:100). Actin staining served as loading-control. (C) HSV-1 DNA replication 333 
assay. Vero cells (150’000 cells/well) were co-transfected with 0.05µg of the HSV replicon 334 
plasmid pHSV-lacO, 0.01µg of the reporter plasmid pSV2EYFP-LacI and 0.05µg of a plasmid 335 
encoding either Rep40/52-LacI (panel k-o), the helicase deficient mutant Rep40/52K340H-336 
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LacI (panel, p-t), wtRep40/52 (panel f-j) or the empty plasmid backbone pcDNA3.1+ (no Rep) 337 
(panel a-e). One day after transfection the cells were superinfected with wt HSV-1 (strain F) 338 
at an MOI of 5. After 16 h, the cells were fixed with 4% paraformaldehyde (PFA), immuno-339 
stained for Rep with a primary mouse (ms) anti Rep-mAb (clone 303.9, Fitzgerald, 1:100) 340 
and a secondary goat (gt) anti-ms IgG(H+L)–Alexa Fluor 594 (Molecular Probes®, 1:500) 341 
(red insets), and then subjected to confocal laser scanning microscopy with an SP2 CLSM 342 
from Leica. The percentage of cells displaying pHSV-lacO replication compartments at stage 343 
I, II, III or IV as well as the number of cells showing numerous foci are indicated. Scale bar = 344 
5µm (D) Graph represents the data shown in panel C. Error bars show standard deviation 345 
(SD) from three independent experiments with 80-100 cells counted in each experiment. 346 
Asterisks indicate statistically significant differences based on a paired two-tail students t-test 347 
(* = p<0.05; ** = p<0.01). (E) The panels l-n and q-s from Fig. 3C are shown as merged 348 
images. The blue insets represent the DAPI stain of the corresponding cells. The degree of 349 
colocalization [%] was calculated using the coloc-function of the software Imaris® (Bitplane). 350 
Abbreviation: n/o = not observed. 351 
352 
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Table 1. primer pairs used for ChIP-qPCR 
# forward reverse 
no RBS/US1 gcttccttgtttggagacca gtccagtcaaactccccaaa 
1 cacgtgcagcatctggtc cgagcaacccacacacaat 
2 atcgtgttgatctgctgcac gaggagatcgccatcgtg 
3 ccctcaagttcttcctcacg ggagtcctggctgtctgttg 
4 caaagcgcttcgaaactacc gggtgtgatagacccacagg 
5 gctaaatggcgactccttcc cgatgtggtccggttgtag 
6 gcctcgtggtggacgtatag acatgatcctggctctcacc 
7 aacggcctatccagcgtact atatagcgcgtacgccaagg 
8 gaccatcgcgttcattaaaaa cgtgagggtgttgatgaagt 
9 gcccgaccgaataaactgta cctggatgtgcttcttaccg  
ICP0 prom. ataagttagccctggcccga gctgcgtctcgctccg 
 Primers were generated using the online tool Primer3® (64, 65). The primer pair for the 
ICP0 promoter (ICP0 prom.) was described elsewhere (40). For all primer pairs the 
efficiency coefficients [E] were determined with serial dilutions of purified HSV-1 DNA 
(strain F) under the same qPCR conditions as described in Fig. 2C and used to 
standardize the %-INPUT calculations. 
